StudyFinder



Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in subjects with IgA nephropathy

This study will evaluate the safety and effectiveness of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

Participation for 27 weeks. visits weekly to receive study medication until week 23, visits every 4 weeks to also include blood and urine collection.

up to $100.00 per visit

Umar Farooq
Kim Hitz - at khitz1@pennstatehealth.psu.edu or 717-531-4924
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04905212
SITE00000982
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of IgA nephropathy confirmed by biopsy
≥ 18 years old and ≤ 70 years old
Able and willing to complete all study visits and tests
Woman of childbearing potential agreeable to use an effective form of birth control
Exclusion Criteria:
History of kidney or other organ transplant
received systemic glucocorticoids or immunosuppressive therapy in previous 3 months
previous or current diagnosis of active tuberculosis
malignant tumor within 10 years
Kidney & Urinary System
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,